Evidence map›Paper›PMID 34093145›Full record

ArticleFrontiers in behavioral neuroscience2021

Marked Mild Cognitive Deficits in Humanized Mouse Model of Alzheimer's-Type Tau Pathology.

Joshua D Cho, Yoon A Kim, Elizabeth E Rafikian, Mu Yang, Ismael Santa-Maria

Open access · goldAbstract read
In one paragraph

Article in Frontiers in behavioral neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A neuron type-specific microexon inbioRxiv : the preprint server for biology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joshua D ChoTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, United States.
Yoon A KimTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, United States.
Elizabeth E RafikianThe Mouse NeuroBehavior Core, Institute for Genomic Medicine, Columbia University, New York, NY, United States.
Mu YangThe Mouse NeuroBehavior Core, Institute for Genomic Medicine, Columbia University, New York, NY, United States.
Ismael Santa-MariaTaub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, United States.
Columbia University · US

Funding

Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
MicroRNA modulation of tau expression and phosphorylation in tauopathyR01NS095922 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SANTA-MARIA PEREZ, ISMAEL · 2016 to 2020
$2.0M
NIA NIH HHS P50 AG008702NINDS NIH HHS R01 NS095922
6 · The paper itself

Abstract

Hyperphosphorylation and the subsequent aggregation of tau protein into neurofibrillary tangles (NFTs) are well-established neuropathological hallmarks of Alzheimer's disease (AD) and associated tauopathies. To further examine the impact and progression of human tau pathology in neurodegenerative contexts, the humanized tau (htau) mouse model was originally created. Despite AD-like tau pathological features recapitulated in the htau mouse model, robustness of behavioral phenotypes has not been fully established. With the ultimate goal of evaluating the htau mouse model as a candidate for testing AD therapeutics, we set out to verify, in-house, the presence of robust, replicable cognitive deficits in the htau mice. The present study shows behavioral data collected from a carefully curated battery of learning and memory tests. Here we report a significant short-term spatial memory deficit in aged htau mice, representing a novel finding in this model. However, we did not find salient impairments in long-term learning and memory previously reported in this mouse model. Here, we attempted to understand the discrepancies in the literature by highlighting the necessity of scrutinizing key procedural differences across studies. Reported cognitive deficits in the htau model may depend on task difficulty and other procedural details. While the htau mouse remains a unique and valuable animal model for replicating late onset AD-like human tau pathology, its cognitive deficits are modest under standard testing conditions. The overarching message is that before using any AD mouse model to evaluate treatment efficacies, it is imperative to first characterize and verify the presence of behavioral deficits in-house.

Indexed as

Alzheimer’s diseasecognitionmouse modelneurodegenerationspatial memorytau pathology

Identifiers

PMID34093145
PMCPMC8175658
OpenAlexW3165680108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.